Scholarlink

<p>With a&#xa0;high prevalence of type&#xa0;2 diabetes, affecting approximately 10% of the adult population, this condition represents a&#xa0;widespread disease. Owing to a&#xa0;decreased age at diagnosis in recent years, coupled with an increased life expectancy, the risk of diabetes complications is rising. Therefore, it is important not to neglect glycemic targets alongside the use of well-evaluated substance classes such as SGLT‑2 inhibitors or incretin mimetics. On average, 10–12&#xa0;years after diagnosis, insulin therapy becomes necessary despite the use of the aforementioned pharmaceuticals. National and international guidelines and recommendations formulate the principle of long-acting insulin administration as an entry point into insulin therapy.</p><p>Since September 2024, insulin icodec, which is administered weekly, has been approved and is available on prescription in Germany. Owing to its special pharmacodynamics, a&#xa0;steady state is reached after approximately 4 weeks, which is why the dosage should be increased weekly. When switching from other delayed insulins, the cumulative weekly dose should be administered in one dose; according to the product information, a&#xa0;single loading dose of 50% of the cumulative weekly dose is recommended.</p><p>In approval studies, the effectiveness is slightly higher than long-acting insulins that are administered daily. The risk of hypoglycemia in the type&#xa0;2 diabetes collective is not higher.</p><p>The weekly dosage form can help to reduce “psychological insulin resistance.”</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Von den klinischen Studien in die Praxis – Erfahrungen mit dem Wocheninsulin Icodec

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Stefan Gölz

摘要

With a high prevalence of type 2 diabetes, affecting approximately 10% of the adult population, this condition represents a widespread disease. Owing to a decreased age at diagnosis in recent years, coupled with an increased life expectancy, the risk of diabetes complications is rising. Therefore, it is important not to neglect glycemic targets alongside the use of well-evaluated substance classes such as SGLT‑2 inhibitors or incretin mimetics. On average, 10–12 years after diagnosis, insulin therapy becomes necessary despite the use of the aforementioned pharmaceuticals. National and international guidelines and recommendations formulate the principle of long-acting insulin administration as an entry point into insulin therapy.

Since September 2024, insulin icodec, which is administered weekly, has been approved and is available on prescription in Germany. Owing to its special pharmacodynamics, a steady state is reached after approximately 4 weeks, which is why the dosage should be increased weekly. When switching from other delayed insulins, the cumulative weekly dose should be administered in one dose; according to the product information, a single loading dose of 50% of the cumulative weekly dose is recommended.

In approval studies, the effectiveness is slightly higher than long-acting insulins that are administered daily. The risk of hypoglycemia in the type 2 diabetes collective is not higher.

The weekly dosage form can help to reduce “psychological insulin resistance.”